Table 2 HPV test results according to sexual behavior and HIV serostatus among the 50 study men who have sex with men (MSM) living in Bamako, Mali
Characteristics | Overall | MSM-exclusively | MSMW | P* | HIV- | HIV+ | P* |
|---|---|---|---|---|---|---|---|
Number | 50 | 38 | 12 | 34 | 16 | ||
Any anal HPV [n (%)] | 35 (70.0) | 25 (65.8) | 10 (83.3) | 0.304 | 21 (61.8) | 14 (87.5) | 0.098 |
Multiple anal HPV [n (%)] | 28 (56.0) | 21 (55.3) | 7 (58.3) | 1.0 | 15 (44.1) | 13 (81.3) | 0.016 |
Anal HR-HPV [n (%)] | 28 (56.0) | 21 (55.3) | 7 (58.3) | 1.0 | 16 (47.1) | 12 (75.0) | 0.076 |
Multiple HR-HPV [n (%)] | 16 (32.0) | 12 (31.6) | 4 (33.3) | 1.0 | 7 (20.6) | 9 (56.3) | 0.021 |
HPV-16 [n (%)] | 12 (24.0) | 6 (15.7) | 6 (50.0) | 0.704 | 5 (14.7) | 7 (43.7) | 0.036 |
HPV-18 [n (%)] | 7 (14.0) | 4 (10.5) | 3 (25.0) | 0.336 | 4 (11.8) | 3 (18.7) | 0.665 |
HPV-16 and HPV-18 [n (%)] | 4 (8.0) | 2 (5.2) | 2 (16.7) | 0.239 | 2 (5.9) | 2 (12.5) | 0.584 |
Any 4-valent vaccine HPV [n (%)]μ | 24 (48.0) | 17 (44.7) | 7 (58.3) | 1.0 | 14 (41.2) | 10 (62.5) | 0.574 |
Multiple 4-valent vaccine HPV [n (%)] | 12 (24.0) | 8 (21.0) | 4 (33.3) | 0.876 | 6 (17.6) | 6 (37.5) | 0.658 |
Any 9-valent vaccine HPV [n (%)]£ | 27 (54.0) | 18 (47.4) | 9 (75.0) | 0.321 | 16 (47.0) | 11 (68.7) | 0.256 |
Multiple 9-valent vaccine HPV [n (%)] | 21 (42.0) | 14 (36.8) | 7 (58.3) | 0.379 | 12 (35.3) | 9 (56.2) | 0.301 |
Any 4-valent vaccine HR-HPV [n (%)]μ | 15 (30.0) | 12 (31.6) | 3 (25.0) | 0.899 | 8 (23.5) | 7 (43.7) | 0.125 |
Multiple 4-valent vaccine HR-HPV [n (%)] | 8 (16.0) | 6 (15.8) | 2 (16.7) | 1.0 | 5 (14.7) | 3 (18.7) | 0.573 |
Any 9-valent vaccine HR-HPV [n (%)]£ | 22 (44.0) | 15 (39.4) | 7 (58.3) | 0.954 | 13 (38.2) | 9 (56.2) | 0.206 |
Multiple 9-valent vaccine HR-HPV [n (%)] | 16 (32.0) | 12 (31.6) | 4 (33.3) | 1.0 | 10 (29.4) | 6 (37.5) | 0.678 |